YY1 and serum lipopolysaccharide activity: So far, there are sporadic clinical trials concerning YY1 as a prognostic predictor in breast cancer, follicular lymphoma, diffuse large B‐cell lymphoma, endotoxemia, and pediatric sepsis70, 72, 73, 76 (Table 3).